Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients
Commercial Sponsor
Novartis Pharmaceuticals
Summary
Eligible patients will be randomised to receive different combinations of treatment, using some of the following 5 novel compounds: siremadlin, crizanlizumab, sabatolimab, LTT462 or NIS793.